Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 14.


Back, David, Marzolini, Catia, Hodge, Catherine, Marra, Fiona ORCID: 0000-0003-1326-1149, Boyle, Alison, Gibbons, Sara, Burger, David and Khoo, Saye
(2021) COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87 (1). 212 - 213.


Marra, Fiona ORCID: 0000-0003-1326-1149, zu Siederdissen, Christoph Hoener, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk-Mahadevan, Sivi, Bicer, Ceyhun, Lonjon-Domanec, Isabelle, Jessner, Wolfgang, Beumont-Mauviel, Maria
et al (show 2 more authors) (2018) Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84 (5). 961 - 971.


Hodge, Catherine, Marra, Fiona ORCID: 0000-0003-1326-1149, Marzolini, Catia, Boyle, Alison, Gibbons, Sara, Siccardi, Marco ORCID: 0000-0002-3539-7867, Burger, David, Back, David and Khoo, Saye
(2020) Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75 (12). 3417 - 3424.


Marra, Fiona ORCID: 0000-0003-1326-1149, Boyle, Alison, Peters, Erica, Morris, Judith, Priest, Matthew, Mcdonald, Natasha and Barclay, Stephen T
(2019) EFFICACY OF 8 WEEKS GLECAPREVIR/PIBRENTASVIR IN ROUTINE CARE OF PATIENTS WITH CIRRHOSIS AND NON GENOTYPE 3 INFECTION. .


Back, David, Belperio, Pamela, Bondin, Mark, Negro, Francesco, Talal, Andrew H, Park, Caroline, Zhang, ZhenZhen, Pinsky, Brett, Crown, Eric, Mensa, Federico J
et al (show 1 more authors) (2019) Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. JOURNAL OF VIRAL HEPATITIS, 26 (8). 951 - 960.


Boyle, Alison, Marra, Fiona ORCID: 0000-0003-1326-1149, Peters, Erica, Datta, Shouren, Ritchie, Trina, Priest, Matthew, Heydtmann, Mathis and Barclay, Stephen T
(2020) Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. JOURNAL OF VIRAL HEPATITIS, 27 (4). 371 - 375.


Schulte, Benjamin, Wuebbolding, Maximilian, Marra, Fiona ORCID: 0000-0003-1326-1149, Port, Kerstin, Manns, Michael P, Back, David, Cornberg, Markus, Stichtenoth, Dirk O, zu Siederdissen, Christoph Hoener and Maasoumy, Benjamin
(2020) Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. OPEN FORUM INFECTIOUS DISEASES, 7 (2).


Bourgeois, Stefan, Curescu, Manuela G, Larrey, Dominique G, Marra, Fiona ORCID: 0000-0003-1326-1149, Dorr, Patrick, Charafeddine, Mariem, Crown, Eric, Bondin, Mark and Back, David J
(2017) Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study. .


Larrey, Dominique, Puoti, Massimo, Piekarska, Anna, Back, David, Marra, Fiona ORCID: 0000-0003-1326-1149, Bondin, Mark, Raheja, Ritu, Zhang, Zhenzhen, Kalluri, Hari V, Marcinak, John
et al (show 1 more authors) (2020) POLYPHARMACY IN HCV-INFECTED PATIENTS WHO USE DRUGS TREATED WITH GLECAPREVIR/PIBRENTASVIR: A REAL-WORLD ANALYSIS FROM 9 COUNTRIES. .


Lampertico, Pietro, Mauss, Stefan, Persico, Marcello, Barclay, Stephen T, Marx, Steven, Lohmann, Kristina, Bondin, Mark, Zhang, ZhenZhen, Marra, Fiona ORCID: 0000-0003-1326-1149, Belperio, Pamela S
et al (show 2 more authors) (2020) Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis. ADVANCES IN THERAPY, 37 (9). 4033 - 4042.


Lampertico, Pietro, Mauss, Stefan, Persico, Marcello, Barclay, Stephen T, Marx, Steven, Lohmann, Kristina, Bondin, Mark, Zhang, ZhenZhen, Marra, Fiona ORCID: 0000-0003-1326-1149, Belperio, Pamela S
et al (show 2 more authors) (2020) Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis (vol 37, pg 4033, 2020). ADVANCES IN THERAPY, 37 (11). 4755 - 4756.


Ferenci, Peter, Bourgeois, Stefan, Buggisch, Peter, Norris, Suzanne, Curescu, Manuela, Larrey, Dominique, Marra, Fiona ORCID: 0000-0003-1326-1149, Kleine, Henning, Dorr, Patrick, Charafeddine, Mariem
et al (show 4 more authors) (2019) Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26 (6). 685 - 696.


Marra, Fiona ORCID: 0000-0003-1326-1149, Smolders, Elise J, El-Sherif, Omar, Boyle, Alison, Davidson, Katherine, Sommerville, Andrew J, Marzolini, Catia, Siccardi, Marco ORCID: 0000-0002-3539-7867, Burger, David, Gibbons, Sara
et al (show 2 more authors) (2021) Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21 (1). 9 - 27.


Marra, Fiona ORCID: 0000-0003-1326-1149, Boyle, Alison, Govender, Chris, Biggart, Lynne, Sills, Laura, Ritchie, Trina and Barclay, Stephen T
(2019) USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT. .

This list was generated on Sat Sep 18 06:58:27 2021 BST.